An aging population, an increase in lifestyle diseases, and rising consumer demand for healthcare are expected to propel India's pharmaceutical industry, currently valued at about $58 billion, to grow to $120-130 billion by 2030 and $400-450 billion by 2047. With up to 74% of FDI permitted and green field venture procedures made simpler, India is establishing itself as a major location for international investors wishing to grow in the life sciences and healthcare industries.
Keywords: India; Pharmaceutical industry, Growth, Global supply
×
How to Cite This Article
Vancouver
Karunakaran N. India’s pharmaceutical industry: Some evidence [Internet]. J Manag Res Anal. 2025 [cited 2025 Sep 15];12(2):133-137. Available from: https://doi.org/10.18231/j.jmra.2025.022
APA
Karunakaran, N. (2025). India’s pharmaceutical industry: Some evidence. J Manag Res Anal, 12(2), 133-137. https://doi.org/10.18231/j.jmra.2025.022
MLA
Karunakaran, N.. "India’s pharmaceutical industry: Some evidence." J Manag Res Anal, vol. 12, no. 2, 2025, pp. 133-137. https://doi.org/10.18231/j.jmra.2025.022
Chicago
Karunakaran, N.. "India’s pharmaceutical industry: Some evidence." J Manag Res Anal 12, no. 2 (2025): 133-137. https://doi.org/10.18231/j.jmra.2025.022